Am J Psychiatry 159:1-2, January 2002
© 2002 American Psychiatric Association
Extending Indications for Long-Term Pharmacotherapy: Opportunities and Challenges
John M. Kane, M.D.
The introduction and evolution of pharmacological treatment in the clinical practice of psychiatry has, in a variety of ways, often been complex and controversial. At the same time, advances in diagnosis and assessment have frequently been driven in no small measure by the availability and potential for the further development of effective pharmacological treatments.
Modern-day psychopharmacology has generally progressed from short-term uncontrolled observations regarding a new class of agents (or a new indication) to placebo-controlled trials involving patients with relatively active or acute symptoms. In many cases, the design and methods of these trials have been more careful and well-replicated than in other areas of medicine because of the nature of psychiatric disorders and the variations in public and professional attitudes toward the use of psychotropic drugs.
Once the short-term effects have been established, the next logical question becomes the indications for and potential benefits (and risks) of continuation and maintenance treatment. For schizophrenia and bipolar illness, years of extensive research were required to convince clinicians and the public that long-term treatment was appropriate and frequently beneficial. Even then, concern about serious adverse effects often led to hesitation and ambivalence on the part of clinicians in recommending long-term treatment.
As other disorders have been better characterized phenomenologically and epidemiologically, the role of psychotropic drugs has been more clearly defined; and as new classes of medications have become available, further opportunities have arisen.
This issue of the Journal includes studies that extend our knowledge regarding continuation and maintenance treatment for chronic obsessive-compulsive disorder (OCD) and bulimia nervosa.
In these studies, continued treatment with sertraline in patients with OCD and continued fluoxetine treatment in patients with bulimia nervosa were shown to be generally superior to placebo in maintaining the gains of acute treatment and in preventing relapse or exacerbation. Some of these trials represent seminal work in this context.
Although these drugs are generally well tolerated and dropout rates resulting from adverse effects were relatively low, completion rates in these trials suggest that a substantial proportion of patients discontinue treatment for reasons other than relapse, exacerbation, or adverse effects.
These studies are extremely important in advancing knowledge as to how effective continued medication administration can be, even in patients with chronic illnesses. This expands the scope of psychopharmacologic treatment, but these advances will need to be worked through in a variety of ways.
Psychiatric disorders remain poorly understood by the public at large, and adequate, consistent reimbursement for mental health services has not been achieved. As a result of these and other factors, many people with these disorders do not receive the potential benefits of effective treatment.
In addition, there continues to be a concern on the part of many patients and families that continuation or maintenance treatment represents a form of drug dependence. As one patient put it, "You mean the data show that once I take this medication for awhile I won’t be able to stop it?" We might suggest that this is a misunderstanding of the message physicians are attempting to convey, but in my experience this is not an idiosyncratic reaction. When this is viewed in the context of a variety of perceived alternative "treatment" options (many of which have vocal proponents), it is easy for patients to be confused and ambivalent about long-term pharmacologic treatment.
It is also clear that despite the enormous effort that goes into drug development and clinical trials, remarkably little attention is devoted to issues around treatment adherence and disease management.
Another report in this issue focuses on antipsychotic medication adherence in comparing typical and atypical antipsychotics. The authors found that on the basis of pharmacy refill records, VA outpatients prescribed typical antipsychotics were without medication for approximately 7 days per month, whereas those prescribed atypical antipsychotics were without medication for approximately 4 days per month.
This apparently enhanced adherence is welcome but modest. The authors conclude that it is imperative that research focus on developing effective interventions to improve medication adherence in patients prescribed antipsychotic treatment.
Although patients with psychotic disorders might have the greatest challenges in terms of adherence, as indications for continuation and maintenance pharmacotherapy extend to a variety of psychiatric disorders, treatment availability, acceptance, and adherence will require appropriate attention. This will further extend the gains made possible by the introduction of better-tolerated antidepressant and antipsychotic medications.
Footnotes
Address reprint requests to Dr. Kane, Department of Psychiatry, Hillside Hospital, Long Island Jewish Medical Center, P.O. Box 38, Glen Oaks, NY 11004; kane{at}lij.edu (e-mail).
This article has been cited by other articles:
|
|
|
|
 
P. J. Morris
Compliance Profile of Depakote ER Compared to Depakote DR and Valproic Acid in Bipolar Patients
Journal of Correctional Health Care,
October 1, 2008;
14(4):
311 - 317.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Sajatovic, J. H. Jenkins, R. Safavi, J. A. West, K. A. Cassidy, W. J. Meyer, and J. R. Calabrese
Personal and Societal Construction of Illness Among Individuals With Rapid-Cycling Bipolar Disorder: A Life-Trajectory Perspective
Am J Geriatr Psychiatry,
September 1, 2008;
16(9):
718 - 726.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Yang, J. C Barner, K. A Lawson, K. L Rascati, J. P Wilson, M L. Crismon, J. Worchel, and C. A Mascarenas
Antipsychotic Medication Utilization Trends Among Texas Veterans: 1997-2002
Ann. Pharmacother.,
September 1, 2008;
42(9):
1229 - 1238.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Mojtabai and M. Olfson
National Trends in Psychotherapy by Office-Based Psychiatrists
Arch Gen Psychiatry,
August 1, 2008;
65(8):
962 - 970.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Higashi, N. Maruta, A. Bernstein, K. Ikenaka, and S. Hitoshi
Mood Stabilizing Drugs Expand the Neural Stem Cell Pool in the Adult Brain Through Activation of Notch Signaling
Stem Cells,
July 1, 2008;
26(7):
1758 - 1767.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H.-w. K. Yang, L. Simoni-Wastila, I. H. Zuckerman, and B. Stuart
Benzodiazepine Use and Expenditures for Medicare Beneficiaries and the Implications of Medicare Part D Exclusions
Psychiatr Serv,
April 1, 2008;
59(4):
384 - 391.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. J. Fochtmann, F. F. Duffy, J. C. West, R. Kunkle, and R. M. Plovnick
Performance in Practice: Sample Tools for the Care of Patients with Major Depressive Disorder
Focus,
January 1, 2008;
6(1):
22 - 35.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. H. Perlis, S. Purcell, J. Fagerness, A. Kirby, T. L. Petryshen, J. Fan, and P. Sklar
Family-Based Association Study of Lithium-Related and Other Candidate Genes in Bipolar Disorder
Arch Gen Psychiatry,
January 1, 2008;
65(1):
53 - 61.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. F. Baldassano
Management of Bipolar Disorder in the Acute and Maintenance Settings
Journal of the American Psychiatric Nurses Association,
November 1, 2007;
13(5_suppl):
S16 - S22.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. F. Goldberg, R. H. Perlis, S. N. Ghaemi, J. R. Calabrese, C. L. Bowden, S. Wisniewski, D. J. Miklowitz, G. S. Sachs, and M. E. Thase
Adjunctive Antidepressant Use and Symptomatic Recovery Among Bipolar Depressed Patients With Concomitant Manic Symptoms: Findings From the STEP-BD
Am J Psychiatry,
September 1, 2007;
164(9):
1348 - 1355.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. B. Busch, H. A. Huskamp, and M. B. Landrum
Quality of Care in a Medicaid Population With Bipolar I Disorder
Psychiatr Serv,
June 1, 2007;
58(6):
848 - 854.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. B. Dixon, D. A. Adler, J. L. Berlant, R. A. Dulit, B. Goldman, A. L. Hackman, D. W. Oslin, S. G. Siris, W. A. Sonis, and M. Valenstein
Best Practices: Psychiatrists and Primary Caring: What Are Our Boundaries of Responsibility?
Psychiatr Serv,
May 1, 2007;
58(5):
600 - 602.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. S. Sachs, A. A. Nierenberg, J. R. Calabrese, L. B. Marangell, S. R. Wisniewski, L. Gyulai, E. S. Friedman, C. L. Bowden, M. D. Fossey, M. J. Ostacher, et al.
Effectiveness of Adjunctive Antidepressant Treatment for Bipolar Depression
N. Engl. J. Med.,
April 26, 2007;
356(17):
1711 - 1722.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Scherk, F. G. Pajonk, and S. Leucht
Second-Generation Antipsychotic Agents in the Treatment of Acute Mania: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Arch Gen Psychiatry,
April 1, 2007;
64(4):
442 - 455.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Streeruwitz, T. R. E. Barnes, J. Fehler, R. Ohlsen, and V. A. Curtis
Pharmacological management of acute mania - does current prescribing practice reflect treatment guidelines?
J Psychopharmacol,
March 1, 2007;
21(2):
206 - 209.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. B. Busch, D. Ling, R. G. Frank, and S. F. Greenfield
Changes in the Quality of Care for Bipolar I Disorder During the 1990s
Psychiatr Serv,
January 1, 2007;
58(1):
27 - 33.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. N. Ghaemi
Ask the Expert: TREATMENT OF PATIENT WITH BIPOLAR DISORDER AND DEPRESSION
Focus,
January 1, 2007;
5(1):
18 - 19.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. A. Hirschfeld
Guideline Watch (November 2005): Practice Guideline for the Treatment of Patients with Bipolar Disorder, 2nd Edition
Focus,
January 1, 2007;
5(1):
34 - 39.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Scott, E. Paykel, R. Morriss, R. Bentall, P. Kinderman, T. Johnson, R. Abbott, and H. Hayhurst
Cognitive-Behavioural Therapy for Severe and Recurrent Bipolar Disorders: Randomised Controlled Trial
Focus,
January 1, 2007;
5(1):
64 - 72.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. M. Koran M.D.
Obsessive-Compulsive Disorder: An Update for the Clinician
Focus,
January 1, 2007;
5(3):
299 - 313.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Edlund and K. M. Harris
Perceived Effectiveness of Medications Among Mental Health Service Users With and Without Alcohol Dependence
Psychiatr Serv,
May 1, 2006;
57(5):
692 - 699.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. E. Simon, E. J. Ludman, M. S. Bauer, J. Unutzer, and B. Operskalski
Long-term Effectiveness and Cost of a Systematic Care Program for Bipolar Disorder.
Arch Gen Psychiatry,
May 1, 2006;
63(5):
500 - 508.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. SCOTT, E. PAYKEL, R. MORRISS, R. BENTALL, P. KINDERMAN, T. JOHNSON, R. ABBOTT, and H. HAYHURST
Cognitive-behavioural therapy for severe and recurrent bipolar disorders: Randomised controlled trial
The British Journal of Psychiatry,
April 1, 2006;
188(4):
313 - 320.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. N Nguyen and S. K Guthrie
Risperidone Treatment of Bipolar Mania
Ann. Pharmacother.,
April 1, 2006;
40(4):
674 - 682.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. H. McAllister-Williams
Relapse prevention in bipolar disorder: a critical review of current guidelines.
J Psychopharmacol,
March 1, 2006;
20(2 Suppl):
12 - 16.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. Scott
Psychotherapy for bipolar disorders - efficacy and effectiveness.
J Psychopharmacol,
March 1, 2006;
20(2 Suppl):
46 - 50.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. H. Young, J. Cookson, B. Elliott, J. S. E. Hellewell, R. H. McAllister-Williams, J. Newham, A. Ogilvie, J. Scott, S. Tyrer, and M. Turner
Managing the aftermath of mania - Newcastle, 2 September 2005: Consensus Meeting Statement.
J Psychopharmacol,
March 1, 2006;
20(2 Suppl):
51 - 54.
[PDF]
|
|
|
|
|
|
|
P. A Marken and R. W Pies
Emerging Treatments for Bipolar Disorder: Safety and Adverse Effect Profiles
Ann. Pharmacother.,
February 1, 2006;
40(2):
276 - 285.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Frye, J. R. Calabrese, M. L. Reed, K. D. Wagner, L. Lewis, J. McNulty, and R. M. A. Hirschfeld
Use of Health Care Services Among Persons Who Screen Positive for Bipolar Disorder
Psychiatr Serv,
December 1, 2005;
56(12):
1529 - 1533.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Mann
The medical management of depression.
N. Engl. J. Med.,
October 27, 2005;
353(17):
1819 - 1834.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Drug treatments for bipolar disorder: 2 - Maintenance, prevention and special situations
DTB,
May 1, 2005;
43(5):
33 - 37.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Drug treatments for bipolar disorder: 1 - Acute manic or depressive
DTB,
April 1, 2005;
43(4):
28 - 32.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K. Das, M. Olfson, M. J. Gameroff, D. J. Pilowsky, C. Blanco, A. Feder, R. Gross, Y. Neria, R. Lantigua, S. Shea, et al.
Screening for Bipolar Disorder in a Primary Care Practice
JAMA,
February 23, 2005;
293(8):
956 - 963.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. D. Jindal and M. E. Thase
Integrating Psychotherapy and Pharmacotherapy to Improve Outcomes Among Patients With Mood Disorders
Focus,
January 1, 2005;
3(1):
114 - 121.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. T. Lewis, E. Kass, and R. M. Klein
An Overview of Primary Care Assessment and Management of Bipolar Disorder
J Am Osteopath Assoc,
June 1, 2004;
104(6_suppl):
S2 - S8.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. T. Lewis
Bipolar Depression in Primary Care: A Hidden Threat
J Am Osteopath Assoc,
June 1, 2004;
104(6_suppl):
S9 - S14.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. J. Bartels, A. R. Dums, T. E. Oxman, L. S. Schneider, P. A. Arean, G. S. Alexopoulos, and D. V. Jeste
Evidence-Based Practices in Geriatric Mental Health Care
Focus,
April 1, 2004;
2(2):
268 - 281.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. N. YATHAM, F. GROSSMAN, I. AUGUSTYNS, E. VIETA, and A. RAVINDRAN
Mood stabilisers plus risperidone or placebo in the treatment of acute mania: International, double-blind, randomised controlled trial
The British Journal of Psychiatry,
February 1, 2003;
182(2):
141 - 147.
[Abstract]
[Full Text]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2002
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
